Chemed Corp. (NYSE:CHE) – KeyCorp raised their FY2017 earnings estimates for Chemed Corp. in a report released on Monday. KeyCorp analyst J. Gurda now expects that the company will earn $4.73 per share for the year, up from their previous estimate of $4.43. KeyCorp currently has a “Hold” rating on the stock. KeyCorp also issued estimates for Chemed Corp.’s FY2018 earnings at $8.91 EPS.

Chemed Corp. (NYSE:CHE) last posted its quarterly earnings results on Thursday, October 26th. The company reported $2.15 earnings per share (EPS) for the quarter, beating the Thomson Reuters’ consensus estimate of $2.00 by $0.15. The business had revenue of $417.40 million for the quarter, compared to analyst estimates of $414.34 million. Chemed Corp. had a return on equity of 27.69% and a net margin of 4.62%. The business’s revenue was up 6.3% compared to the same quarter last year. During the same period in the prior year, the company posted $1.73 EPS.

TRADEMARK VIOLATION WARNING: “KeyCorp Weighs in on Chemed Corp.’s FY2017 Earnings (CHE)” was first published by American Banking News and is owned by of American Banking News. If you are reading this article on another domain, it was copied illegally and reposted in violation of United States and international trademark and copyright legislation. The legal version of this article can be read at https://www.americanbankingnews.com/2017/11/02/keycorp-weighs-in-on-chemed-corp-s-fy2017-earnings-che.html.

Other analysts have also issued research reports about the company. Zacks Investment Research raised Chemed Corp. from a “hold” rating to a “buy” rating and set a $216.00 price objective on the stock in a report on Monday, September 18th. Oppenheimer Holdings, Inc. lifted their price objective on Chemed Corp. from $200.00 to $220.00 and gave the stock an “outperform” rating in a report on Thursday, July 27th. TheStreet lowered Chemed Corp. from a “b+” rating to a “c+” rating in a report on Tuesday, July 25th. Finally, Royal Bank Of Canada reissued a “hold” rating and set a $209.00 price objective on shares of Chemed Corp. in a report on Monday, July 31st. Four analysts have rated the stock with a hold rating and one has issued a buy rating to the stock. The company has a consensus rating of “Hold” and a consensus price target of $224.33.

In related news, CEO Kevin J. Mcnamara sold 10,000 shares of the firm’s stock in a transaction that occurred on Tuesday, October 31st. The stock was sold at an average price of $223.42, for a total transaction of $2,234,200.00. Following the completion of the transaction, the chief executive officer now owns 170,016 shares in the company, valued at approximately $37,984,974.72. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this link. Also, insider Spencer S. Lee sold 1,000 shares of the firm’s stock in a transaction that occurred on Friday, September 1st. The stock was sold at an average price of $197.46, for a total value of $197,460.00. Following the transaction, the insider now owns 37,809 shares of the company’s stock, valued at approximately $7,465,765.14. The disclosure for this sale can be found here. Insiders have sold a total of 12,250 shares of company stock valued at $2,698,968 in the last 90 days. 4.90% of the stock is owned by corporate insiders.

Institutional investors have recently bought and sold shares of the stock. Acrospire Investment Management LLC bought a new position in shares of Chemed Corp. during the 2nd quarter worth approximately $120,000. Pacad Investment Ltd. lifted its position in shares of Chemed Corp. by 250.0% during the 2nd quarter. Pacad Investment Ltd. now owns 700 shares of the company’s stock worth $143,000 after buying an additional 500 shares during the period. IFP Advisors Inc lifted its position in shares of Chemed Corp. by 1,504.5% during the 3rd quarter. IFP Advisors Inc now owns 706 shares of the company’s stock worth $143,000 after buying an additional 662 shares during the period. Zurcher Kantonalbank Zurich Cantonalbank lifted its position in shares of Chemed Corp. by 12.8% during the 2nd quarter. Zurcher Kantonalbank Zurich Cantonalbank now owns 731 shares of the company’s stock worth $150,000 after buying an additional 83 shares during the period. Finally, MCF Advisors LLC bought a new position in shares of Chemed Corp. during the 3rd quarter worth approximately $152,000. Institutional investors and hedge funds own 97.24% of the company’s stock.

About Chemed Corp.

Chemed Corporation purchases, operates and divests subsidiaries engaged in various business activities. The Company operates through two segments: the VITAS segment (VITAS) and the Roto-Rooter segment (Roto-Rooter). The Company’s VITAS provides hospice and palliative care services to its patients through a network of physicians, registered nurses, home health aides, social workers, clergy and volunteers.

Earnings History and Estimates for Chemed Corp. (NYSE:CHE)

Receive News & Ratings for Chemed Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chemed Corp. and related companies with MarketBeat.com's FREE daily email newsletter.